Effectiveness of 18F-FDG PET/CT in detection of loco-regional recurrence of breast cancer in comparison to CT alone

Khalifa, Mai; Gaber, Mohmed; Soliman, Walid

doi:10.21608/smj.2019.40810

Effectiveness of 18F-FDG PET/CT in detection of loco-regional recurrence of breast cancer in comparison to CT alone

Document Type : Original Article

Authors

¹ Department of Clinical Oncology & Nuclear Medicine, Faculty of Medicine, Sohag University.

² Department of Clinical Oncology, Faculty of Medicine, Sohag University.

³ Department of Nuclear Medicine, National cancer institute-Cairo.

10.21608/smj.2019.40810

Main Subjects

Oncology and Nuclear Medicine.

References

1. Taghipour M, Wray R, Sheikhbahaei S, Wright JL and Subramaniam RM: FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer.AJR Am J Roentgenol. 2016; 206(4): 846-55.

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018.

3. Elatar I, Cancer registration, NCI Egypt 2001. Cairo, Egypt, National Cancer Institute 2002. 2002.

4. Dubey AK, Gupta U and Jain S: Breast cancer statistics and prediction methodology: a systematic review and analysis.Asian Pac J Cancer Prev. 2015; 16(10): 4237-45.

5. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP: The transcriptional repressor Snail promotes mammary tumor recurrence.Cancer Cell. 2005; 8(3): 197-209.

6. Jung KW, Won YJ, Kong HJ and Lee ES: Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015.Cancer Res Treat. 2018; 50(2): 303-316.

7. Kim SJ, Moon WK, Cho N and Chang JM: The detection of recurrent breast cancer in patients with a history of breast cancer surgery: comparison of clinical breast examination, mammography and ultrasonography.Acta Radiol. 2011; 52(1): 15-20.

8. Avril S, Muzic RF, Jr., Plecha D, Traughber BJ, Vinayak S: (1)(8)F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.J Nucl Med. 2016; 57 Suppl 1: 34s-9s.

9. Blodgett TM, Meltzer CC and Townsend DW: PET/CT: form and function.Radiology. 2007; 242(2): 360-85.

10. Groheux D, Hatt M, Hindie E, Giacchetti S, De Cremoux P: Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.Cancer. 2013; 119(11): 1960-8.

11. Pan L, Han Y, Sun X, Liu J and Gang H: FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis.J Cancer Res Clin Oncol. 2010; 136(7): 1007-22.

12. Aukema TS, Straver ME, Peeters MJ, Russell NS, Gilhuijs KG: Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.Eur J Cancer. 2010; 46(18): 3205-10.

13. Parmar AD, Sheffield KM, Vargas GM, Han Y, Chao C: Quality of post-treatment surveillance of early stage breast cancer in Texas.Surgery. 2013; 154(2): 214-25.

14. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L and Israel O: The role of FDG-PET/CT in suspected recurrence of breast cancer.Cancer. 2006; 107(11): 2545-51.

15. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK and Wahl RL: Initial experience with FDG-PET/CT in the evaluation of breast cancer.Eur J Nucl Med Mol Imaging. 2006; 33(3): 254-62.

16. Haug AR, Schmidt GP, Klingenstein A, Heinemann V, Stieber P: F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers.J Comput Assist Tomogr. 2007; 31(4): 629-34.

17. Dirisamer A, Halpern BS, Flory D, Wolf F, Beheshti M: Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.Eur J Radiol. 2010; 73(2): 294-9.

18. Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M: Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management.Cancer. 2011; 117(8): 1621-9.

19. Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J: Evaluation of (1)(8)F-FDG PET/MRI, (1)(8)F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.Eur J Radiol. 2016; 85(2): 459-65.

20. Grassetto G, Fornasiero A, Otello D, Bonciarelli G, Rossi E: 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.Eur J Radiol. 2011; 80(3): 828-33.

21. Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M: Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer.Eur J Nucl Med Mol Imaging. 2011; 38(2): 293-301.